This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Digging into the potential of AYVAKIT (avapritinib) as part of treatment in patients with non advanced systemic mastocytosis
Ticker(s): BPMCWho's the expert?
Institution: MD Anderson
- Associate Professor of Medicine, Department of Leukemia at MD Anderson.
- Manages 40 patients with systemic mastocytosis.
- Research focus is on myeloproliferative neoplasms (MPNs). Heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research; leads number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis (PI on APEX, SUMMIT, HARBOR).
Interview GoalThis conversation will focus on discussing the recent positive top-line results announcement by Blueprint Medicines for Ayvakit (avapritinib) achieving primary and all key secondary endpoints from the PIONEER trial of in treating patients with non-advanced systemic mastocytosis
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
